Therapy of juvenile idiopathic arthritis in early adulthood with biologics. Transition from pediatric to adult care;Biologikatherapie der juvenilen idiopathische arthritis im jungen erwachsenenalter. Übergang von der pädiatrischen in die erwachsenenversorgung

Zeitschrift fur Rheumatologie

Volumn 73, Issue 6, 2014, Pages 532-540

  Niewerth, M ^a   Minden, K ^a   Klotsche, J ^a   Horneff, G ^b  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b Asklepios Kinderklinik St Augustin GmbH ^*  (Germany)

Author keywords

Biologics register; Disease modifying antirheumatic drugs; Interface pediatric and adult rheumatology; Transition to adult care; Young adult

Indexed keywords

ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; BIOLOGICAL PRODUCT;

ADULT; ARTICLE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; TRANSITION TO ADULT CARE; TREATMENT OUTCOME; ADOLESCENT; ARTHRITIS, JUVENILE; DRUG USE; FEMALE; GERMANY; MALE; PEDIATRICS; PREVALENCE; REGISTER; RHEUMATOLOGY; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; DRUG UTILIZATION REVIEW; FEMALE; GERMANY; HUMANS; MALE; PEDIATRICS; PREVALENCE; REGISTRIES; RHEUMATOLOGY; TRANSITION TO ADULT CARE; YOUNG ADULT;

EID: 84929132239     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-014-1378-z     Document Type: Article

References (21)

1. Baszis K, Garbutt J, Toib D et al (2011) Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum 63(10):3163-3168
2. Bazarra-Castro MÁ, Sievers C, Schwarz HP et al (2012) Changes in BMI and management of patients with childhood onset growth hormone deficiency in the transition phase. Exp Clin Endocrinol Diabetes 120:507-510
3. Consolaro A, Bracciolini G, Ruperto N et al (2012) Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 64:2366-2374
4. Foster HE, Marshall N, Myers A et al (2003) Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 48:767-775 (Pubitemid 36302014)
5. Giannini EH, Brewer EJ, Kuzmina N et al (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group. N Engl J Med 326:1043-1049
6. Hanova P, Pavelka K, Dostal C et al (2006) Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003. Clin Exp Rheumatol 24(5):499-507 (Pubitemid 44913611)
7. Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63(12):1638-1644 (Pubitemid 39573695)
8. Hyrich KL, Lal SD, Foster HE et al (2010) Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the childhood arthritis prospective study. Rheumatology (Oxford) 49(1):116-122
9. Iglesias E, Torrente-Segarra V, Bou R et al (2013) Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment. Rheumatol Int. doi:10.1007/s00296-013-2884-z (Epub ahead of print)
10. McErlane F, Foster H, Davies R et al (2013) Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 52(10):1905-1913
11. McErlane F, Beresford MW, Baildam EM et al (2013) Childhood Arthritis Prospective Study (CAPS). Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis 72(12):1983-1988
12. Minden K, Niewerth M, Listing J et al (2002) Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 46(9):2392-2401
13. Minden K, Niewerth M, Zink A et al (2012) Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 51(8):1407-1415
14. Minden K, Klotsche J, Niewerth M et al (2013) Biologikaregister JuMBO - Langzeitsicherheit von Biologikatherapie bei juveniler idiopathischer Arthritis. Z Rheumatol 72(4):339-346
15. Niewerth M, Minden K (2011) Transition - Der schwierige Weg des Übergangs von der pädiatrischen in die internistische Rheumatologie. Arthritis Rheum (Munch) 31(4):265-269
16. Nordal E, Zak M, Aalto K, Berntson L et al (2011) Nordic Study Group of Pediatric Rheumatology. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 63(9):2809-2818
17. Oen K, Tucker L, Huber AM et al (2009) Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, prospective inception cohort study. Arthritis Rheum 61(8):1077-1086
18. Rausch JR, Hood KK, Delamater A et al (2012) Changes in treatment adherence and glycemic control during the transition to adolescence in type 1 diabetes. Diabetes Care 35(6):1219-1224
19. Ruperto N, Martini A (2011) Current medical treatments for juvenile idiopathic arthritis. Front Pharmacol 2(10):60
20. Tynjälä P, Vähäsalo P, Tarkiainen M et al (2011) Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTEJIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 70(9):1605-1612
21. Vidqvist KL, Malin M, Varjolahti-Lehtinen T et al (2013) Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies. Rheumatology 52(11):1999-2003